Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BioNTech (BNTX) stocks

BioNTech stock has moved 7.32% from yesterday's closing price. Learn how to easily invest in BioNTech stock.

BioNTech (BNTX) is a leading biotechnology business based in the US. It opened the day at $140.24 after a previous close of $134.04. During the day the price has varied from a low of $138.08 to a high of $144.2799. The latest price was $143.8574 (25 minute delay). BioNTech is listed on the NASDAQ and employs 3,082 staff. All prices are listed in US Dollars.

How to buy stocks in BioNTech

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BNTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BioNTech stock price (NASDAQ:BNTX)

Use our graph to track the performance of BNTX stocks over time.

BioNTech shares at a glance

Information last updated 2022-06-27.
Previous close$134.04
Change $9.82
Change % 7.3242%
Volume 1,532,414
Information last updated 2022-06-20.
52-week range$119.73 - $457.93
50-day moving average $153.45
200-day moving average $214.83
Wall St. target price$253.57
PE ratio 2.4236
Dividend yield $0 (1.33%)
Earnings per share (TTM) $51.64

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
3.8 / 5
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy BioNTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BioNTech price performance over time

Historical closes compared with the close of $143.8574 from 2022-06-24

1 week (2022-06-17) 14.96%
1 month (2022-05-26) -9.04%
3 months (2022-03-24) -15.58%
6 months (2021-12-23) -43.65%
1 year (2021-06-25) -37.46%
2 years (2020-06-26) 131.54%
3 years (2019-06-23) N/A
5 years (2017-06-23) N/A

Is BioNTech under- or over-valued?

Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

BioNTech's P/E ratio

BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, BioNTech shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

BioNTech's PEG ratio

BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0449. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.


BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $17.8 billion.

The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.

BioNTech financials

Revenue TTM $23.3 billion
Operating margin TTM 75.98%
Gross profit TTM $16.1 billion
Return on assets TTM 90.32%
Return on equity TTM 139.59%
Profit margin 55.2%
Book value $65.47
Market capitalisation $30.4 billion

TTM: trailing 12 months

BioNTech share dividends


Dividend payout ratio: 3.95% of net profits

Recently BioNTech has paid out, on average, around 3.95% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), BioNTech shareholders could enjoy a 1.33% return on their shares, in the form of dividend payments. In BioNTech's case, that would currently equate to about $0 per share.

While BioNTech's payout ratio might seem low, this can signify that BioNTech is investing more in its future growth.

BioNTech's most recent dividend payout was on 16 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 1 June 2022 (the "ex-dividend date").

BioNTech share price volatility

Over the last 12 months, BioNTech's shares have ranged in value from as little as $119.7341 up to $457.9346. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioNTech's is -0.2923. This would suggest that BioNTech's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BioNTech has bucked the trend.

BioNTech overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc. ; Sanofi S.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site